Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Abstract Background To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real world clinical use and to evaluate the +86–571-87,236,876 predictive c...

Full description

Bibliographic Details
Main Authors: Jianya Zhou, Jing Zheng, Xiaochen Zhang, Jing Zhao, Yanping Zhu, Qian Shen, Yuehong Wang, Ke Sun, Zeying Zhang, Zhijie Pan, Yihong Shen, Jianying Zhou
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Cancer
Subjects:
Crizotinib
ALK
Non-small cell lung cancer
Efficacy
Pemetrexed
Online Access:http://link.springer.com/article/10.1186/s12885-017-3720-8

Internet

http://link.springer.com/article/10.1186/s12885-017-3720-8

Similar Items